Sangamo Therapeutics (NASDAQ:SGMO) PT Lowered to $3.00 at HC Wainwright
Sangamo Therapeutics (NASDAQ:SGMO – Free Report) had its target price trimmed by HC Wainwright from $5.00 to $3.00 in a report published on Monday, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q4 2023 earnings at ($0.24) EPS, FY2023 earnings at […]
More Stories
Nuveen Asset Management LLC Purchases 27,136 Shares of Bath & Body Works, Inc. (NYSE:BBWI)
Nuveen Asset Management LLC lifted its holdings in shares of Bath & Body Works, Inc. (NYSE:BBWI – Free Report) by...
Nuveen Asset Management LLC Acquires 287,739 Shares of Patrick Industries, Inc. (NASDAQ:PATK)
Nuveen Asset Management LLC lifted its holdings in Patrick Industries, Inc. (NASDAQ:PATK – Free Report) by 495.5% during the fourth...
Nuveen Asset Management LLC Lowers Holdings in Texas Capital Bancshares, Inc. (NASDAQ:TCBI)
Nuveen Asset Management LLC decreased its holdings in Texas Capital Bancshares, Inc. (NASDAQ:TCBI – Free Report) by 3.5% in the...
Millennium Management LLC Has $16.37 Million Stake in Gentex Co. (NASDAQ:GNTX)
Millennium Management LLC raised its holdings in Gentex Co. (NASDAQ:GNTX – Free Report) by 888.7% in the fourth quarter, according...
Nuveen Asset Management LLC Cuts Position in Loews Co. (NYSE:L)
Nuveen Asset Management LLC lessened its holdings in Loews Co. (NYSE:L – Free Report) by 3.3% during the fourth quarter,...
90 Percent of US Companies Plan to Reshore Amid Tariffs, Allianz Survey Finds
By Tom Ozimek Nine out of 10 U.S. companies say they expect to bring some or all of their production...